Quantinno Capital Management LP Purchases 4,516 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Quantinno Capital Management LP lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 27.9% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 20,706 shares of the medical research company's stock after buying an additional 4,516 shares during the quarter. Quantinno Capital Management LP's holdings in Charles River Laboratories International were worth $4,078,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Boston Trust Walden Corp increased its position in Charles River Laboratories International by 2.8% in the second quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company's stock worth $41,381,000 after buying an additional 5,375 shares during the period. Quest Partners LLC grew its position in shares of Charles River Laboratories International by 135,175.0% during the second quarter. Quest Partners LLC now owns 5,411 shares of the medical research company's stock worth $1,118,000 after acquiring an additional 5,407 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Charles River Laboratories International by 3.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock worth $22,060,000 after acquiring an additional 3,714 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Charles River Laboratories International by 6.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company's stock valued at $101,483,000 after purchasing an additional 32,311 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock valued at $346,821,000 after purchasing an additional 509,163 shares during the period. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Trading Up 5.2 %

Shares of NYSE CRL traded up $9.94 during mid-day trading on Monday, hitting $201.75. 629,818 shares of the company traded hands, compared to its average volume of 619,012. The business has a 50 day moving average of $194.10 and a two-hundred day moving average of $203.67. The stock has a market capitalization of $10.32 billion, a price-to-earnings ratio of 24.01, a PEG ratio of 4.95 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1 year low of $176.48 and a 1 year high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. During the same period last year, the company posted $2.72 earnings per share. The business's revenue for the quarter was down 1.6% on a year-over-year basis. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CRL. Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research note on Thursday, November 7th. UBS Group raised their target price on Charles River Laboratories International from $240.00 to $250.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Redburn Atlantic initiated coverage on Charles River Laboratories International in a research report on Monday, October 14th. They set a "sell" rating and a $151.00 price target for the company. Citigroup lowered Charles River Laboratories International from a "neutral" rating to a "sell" rating and lowered their price target for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. Finally, Bank of America downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $250.00 to $215.00 in a report on Wednesday, October 2nd. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $214.38.

Insider Buying and Selling

In related news, Director Richard F. Wallman sold 6,621 shares of the company's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 1.30% of the stock is owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).